2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Andree Blaukat

Session 11 – From Precision Medicine to Precision Health
Date: 24 July (Friday) 10:40 – 12:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform


Andree Blaukat

SVP, Global Head Translational Innovation Platform Oncology
Merck KGaA



 

Dr. Andree Blaukat serves as Senior Vice President and Head of the Translational Innovation Platform Oncology with responsibility for the Healthcare research portfolio of targeted oncology therapeutics. In this role, Andree leads a team of about 100 scientists, technicians and support staff in Darmstadt/Germany and Billerica/US. Andree has served in several other leadership roles in Oncology R&D during his 18-year tenure at Merck, focusing on drug discovery and translational research on oncology. Prior to joining Merck, Andree was a Junior Group Leader and lecturer for pharmacology and toxicology at the Institute of Pharmacology at the Ruprecht-Karls-University Heidelberg,/Germany. Before this assignment he was Postdoctoral Fellow at the Ludwig Institute for Cancer Research in Uppsala/Sweden.  He obtained his PhD in biochemistry from the Universities of Mainz & Darmstadt/Germany in 1997. Andree is co-organizer of the “Perspective Lectures in Oncology” at the Johann-Wolfgang-Goethe University Frankfurt/Germany, initiated in 2010. He has published more than 60 scientific manuscripts and book chapters as well as more than 30 patents.


Speech title & Synopsis

Challenges and opportunities for Precision Medicine in Oncology

Precision Medicine has revolutionized the treatment of a number of cancers and will likely also impact the way we treat other disease in future. In my presentation I will explain the concept of Precision Medicine in oncology using recent examples, highlight some of the successes, but also discuss challenges and limitations of this approach. I will also talk about opportunities how Precision Medicines can could be developed more efficiently and faster in future.